Evidence on the Impact of Pharmacogenetics to Treat and Manage Asthma-Reference-Cited by-同舟云学术

Evidence on the Impact of Pharmacogenetics to Treat and Manage Asthma

Published:2022 Issue: Volume: Page:1-15
ISSN:
Container-title:Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy
language:
Short-container-title:

Author:

Nie Xiaoyan,Zhao Yuxuan,Lu Christine Y.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-030-50247-8_136-1

Reference47 articles.

1. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, Hakuno H, Fukunaga K, Suzuki Y, Kanazawa M, Yamaguchi K. Leukotriene C4 synthase gene A(−444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics. 2002;12(7):565–70. https://doi.org/10.1097/00008571-200210000-00009.

2. Cai C, Zhou MX, Li YP, Chen CS. Association of leukotriene gene polymorphisms with response to antileukotriene treatment in patients with asthma. Zhonghua Jie He He Hu Xi Za Zhi. 2011;34(5):362–6. Chinese

3. Choudhry S, Que LG, Yang Z, Liu L, Eng C, Kim SO, Kumar G, Thyne S, Chapela R, Rodriguez-Santana JR, Rodriguez-Cintron W, Avila PC, Stamler JS, Burchard EG. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics. 2010;20(6):351–8. https://doi.org/10.1097/FPC.0b013e328337f992.

4. CPIC’s levels for genes/drugs. CPIC®. https://cpicpgx.org/prioritization/#cpicLevels [May 23, 2021 @3:56 pm].

5. Dijkstra A, Koppelman GH, Vonk JM, Bruinenberg M, Schouten JP, Postma DS. Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol. 2008;121(6):1510–3. https://doi.org/10.1016/j.jaci.2008.04.015.